NuCana plc NCNA
Regular-session close
After hours · Nov 19, 7:34 PM ET
- YTD
- -80.05%
- 1 year
- -78.56%
5D -0.0790 (-8.66%)
- Market cap
- 2.99M
- Shares out
- 3.93M
- Forward P/E
- -0.13
- YTD return
- -80.05%
- 1-year return
- -78.56%
- 50-day average
- 1.50
- 200-day average
- 3.56
- Enterprise value
- 59.40M
- Volume
- 110.98K
- Avg volume
- 116.56K
- Open
- 0.858
- Previous close
- 0.8328
- Day's range
- 0.639 – 0.8798
- 52-week range
- 0.639 – 4.55
- Beta
- 1.04
- Price target
- 64.50 (+8882.0%)
Key statistics
- Price / book
- 0.17
- Free cash flow
- -7.63M
- Total cash
- 11.64M
- Total debt
- 281.00K
- Return on equity
- -180.77%
Fundamental scorecard
5 of 25 checks passed on NCNA’s reported financials
5of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend No data
Statements to Sep 30, 2026.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 19, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Jul 23, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Jul 22, 2024 | Oppenheimer | main | Outperform | Outperform |
| Apr 1, 2024 | Oppenheimer | reit | Outperform | Outperform |
| Nov 21, 2023 | Oppenheimer | reit | Outperform | Outperform |
| Sep 6, 2023 | Truist Securities | reit | Buy | Buy |
About NuCana plc
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- nucana.com
News
NuCana Reports Third Quarter 2026 Financial Results and Provides Business Update
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe
NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update
NuCana Appoints Ian Webster as Chief Financial Officer
NuCana Reports First Quarter 2026 Financial Results and Provides Business Update
NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update
NuCana Appoints Theresa Bruce as Chief Operating Officer
NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma
NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China
Your note
Sign in to keep a note on NCNA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Carlyle Group Inc. | 5.04% | 133,333 | 161.33K | Sep 29, 2024 |
| Baillie Gifford and Company | 1.39% | 36,704 | 44.41K | Sep 29, 2024 |
| Acadian Asset Management. LLC | 0.89% | 23,624 | 28.59K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.64% | 16,818 | 20.35K | Sep 29, 2024 |
| Glass Jacobson Investment Advisors LLC | 0.57% | 15,000 | 18.15K | Sep 29, 2024 |
| UBS Group AG | 0.48% | 12,604 | 15.25K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.03% | 751 | 908 | Oct 30, 2024 |
